Focused On-demand Library for DnaJ homolog subfamily C member 30, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96LL9

UPID:

DJC30_HUMAN

Alternative names:

Williams-Beuren syndrome chromosomal region 18 protein

Alternative UPACC:

Q96LL9; Q9BSG8

Background:

DnaJ homolog subfamily C member 30, mitochondrial, also known as Williams-Beuren syndrome chromosomal region 18 protein, plays a pivotal role in mitochondrial function. It is a mitochondrial protein enriched in neurons, acting as a regulator of mitochondrial respiration. This protein associates with the ATP synthase complex, facilitating ATP synthesis. Additionally, it may serve as a chaperone protein, involved in the turnover of mitochondrial complex I N-module subunits, especially those damaged by oxidative stress, thereby contributing to complex I functional efficiency.

Therapeutic significance:

The protein is linked to an autosomal recessive form of Leber hereditary optic neuropathy, a condition characterized by bilateral painless loss of central vision. Understanding the role of DnaJ homolog subfamily C member 30, mitochondrial, could open doors to potential therapeutic strategies for this mitochondrial disease, highlighting its importance in medical research.